𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines

✍ Scribed by Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Antoinette Wozniak; Fazlul H. Sarkar

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
782 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Epidermal growth factor receptor mutatio
Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer : Impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors
✍ Victor Cohen; Jason S. Agulnik; Celina Ang; Goulnar Kasymjanova; Gerald Batist; πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 206 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Somatic mutations in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to EGFR‐tyrosine kinase inhibitors (EGFR‐TKI) in patients with nonsmall cell lung cancer (NSCLC). ## METHODS: The authors tested the possibility that nucleoti

Frequent central nervous system failure
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer
✍ Young Joo Lee; Hye Jin Choi; Se Kyu Kim; Joon Chang; Jin Wook Moon; In Kyu Park; πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 181 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: We investigated the risk of central nervous system (CNS) failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) in Korean patients with nonsmall‐cell lung cancer (NSCLC) ## METHODS: We retrospectively evaluated the p

Trying to compose the puzzle with all th
Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
✍ Massimo Di Maio; Cesare Gridelli; Nicola Normanno; Francesco Perrone; Fortunato πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 162 KB

## Abstract Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown promising activity in patients with non‐small cell lung cancer (NSCLC). Gefitinib has been the first of these drugs to be licensed for third‐line treatment of advanced NSCLC patients. Mor

Targeted inhibition of the epidermal gro
Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 (β€˜Iressa’) induces cell-cycle arrest and inhibits proliferation in prostate cancer cells
✍ Alessandro Sgambato; Andrea Camerini; Beatrice Faraglia; Raffaele Ardito; Gabrie πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 297 KB πŸ‘ 2 views

## Abstract The epidermal growth factor (EGF) plays a role in the development of prostate cancer, which becomes essential after androgen resistance has emerged. The EGF receptor (EGFR) is therefore a potential target for anticancer therapy. We evaluated the effects of ZD1839 (β€˜Iressa’), an orally a

ZD1839 (Iressa), a novel epidermal growt
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
✍ Neil G. Anderson; Tawhid Ahmad; Kai Chan; Richard Dobson; Nigel J. Bundred πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 French βš– 192 KB πŸ‘ 1 views

Overexpression of the growth factor receptors EGFR and erbB2 occurs frequently in several human cancers and is associated with aggressive tumour behaviour and poor patient prognosis. We have investigated the effects of ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, on the growth, in vitro